Literature DB >> 6140815

Different effects of types A and B botulinum toxin on transmitter release at the rat neuromuscular junction.

L C Sellin, S Thesleff, B R Dasgupta.   

Abstract

Blockade of neuromuscular transmission was produced in the lower hind limb of the rat by local injection of either crystalline type A botulinum toxin or purified type B botulinum neurotoxin. At 1, 3, 5 and 7 days after injection, the extensor digitorum longus nerve-muscle preparation was excised and analyzed in vitro for alterations in spontaneous and nerve stimulus-evoked quantal transmitter release. Muscles receiving type A toxin were paralyzed up to and including 7 days after injection. Muscles treated with type B toxin, although completely paralyzed at 1 and 3 days, twitched in response to nerve stimulation at 5 and 7 days after injection. Both toxins induced a marked decrease in the frequency of miniature endplate potentials but type A did so to a greater extent. The remaining population of miniature endplate potentials contained a greater frequency of potentials with small or large amplitudes and prolonged rise times compared to normal muscle. These changes were more pronounced with type A toxin than with type B toxin. In the presence of alpha-dinitrophenol (1 mM), high frequency, fast-rising miniature endplate potentials of uniform size reappeared. High K+ (20 mM) was less effective in this respect. At 3 days after toxin injection nerve impulse evoked transmitter release was reduced more for type A treated muscles than for type B. However, 3,4-diaminopyridine, an agent which increases nerve-evoked transmitter release by increasing Ca2+ influx, was more effective in reversing the paralysis in type A than in type B-treated muscles.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6140815     DOI: 10.1111/j.1748-1716.1983.tb07317.x

Source DB:  PubMed          Journal:  Acta Physiol Scand        ISSN: 0001-6772


  9 in total

1.  Function Suggests Nano-Structure: Quantitative Structural Support for SNARE-Mediated Pore Formation.

Authors:  Ilan Hammel; Isaac Meilijson
Journal:  Neurotox Res       Date:  2015-09-25       Impact factor: 3.911

Review 2.  Properties and use of botulinum toxin and other microbial neurotoxins in medicine.

Authors:  E J Schantz; E A Johnson
Journal:  Microbiol Rev       Date:  1992-03

3.  A study of synchronization of quantal transmitter release from mammalian motor endings by the use of botulinal toxins type A and D.

Authors:  J Molgó; L S Siegel; N Tabti; S Thesleff
Journal:  J Physiol       Date:  1989-04       Impact factor: 5.182

Review 4.  New concepts in botulinum toxin therapy.

Authors:  G E Borodic; L B Pearce
Journal:  Drug Saf       Date:  1994-09       Impact factor: 5.606

5.  A preclinical evaluation of aminopyridines as putative therapeutic agents in the treatment of botulism.

Authors:  L L Simpson
Journal:  Infect Immun       Date:  1986-06       Impact factor: 3.441

Review 6.  Botulinum toxin B: a review of its therapeutic potential in the management of cervical dystonia.

Authors:  David P Figgitt; Stuart Noble
Journal:  Drugs       Date:  2002       Impact factor: 9.546

7.  Distinct sites of action of clostridial neurotoxins revealed by double-poisoning of mouse motor nerve terminals.

Authors:  M Gansel; R Penner; F Dreyer
Journal:  Pflugers Arch       Date:  1987-08       Impact factor: 3.657

8.  Reductive methylation of lysine residues of botulinum neurotoxin types A and B.

Authors:  V Sathyamoorthy; B R DasGupta
Journal:  Mol Cell Biochem       Date:  1988-09       Impact factor: 3.396

9.  Interaction of 125I-labeled botulinum neurotoxins with nerve terminals. I. Ultrastructural autoradiographic localization and quantitation of distinct membrane acceptors for types A and B on motor nerves.

Authors:  J D Black; J O Dolly
Journal:  J Cell Biol       Date:  1986-08       Impact factor: 10.539

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.